CA
NZ
UK
AU
IND
US
Merck (NYSE:MRK) presented one-year results on October 12, 2026 for remigromig, its candidate for diabetic macular edema, a swelling of the central retina caused by leaking blood vessels in people with diabetes. Vision improved by 9.1 letters and 8.7 letters in the two remigromig …
First Tracks Biotherapeutics (NASDAQ:TRAX) reported positive Phase 1b data in celiac disease on October 12, 2026, and shares traded between USD 36.78 and USD 38.61 premarket against a USD 31.85 close. That is a gain of about 15.5% to 21.2%, simple arithmetic on published …
Bristol Myers Squibb (NYSE:BMY) announced on October 12, 2026 that admilparant achieved the primary endpoint in idiopathic pulmonary fibrosis at the 60 mg dose but did not reach statistical significance at 120 mg. Idiopathic pulmonary fibrosis is a progressive lung disease in which scar …
The October 12, 2026 report asked whether Biohaven's encaleret succeeded in Phase 3 for a rare calcium-regulation disorder. Company materials show that encaleret is developed by BridgeBio Pharma (NASDAQ:BBIO), not by Biohaven, so the attribution appears wrong. The drug targets autosomal dominant hypocalcemia type …
JPMorgan raised its rating on Biogen (NASDAQ:BIIB) to Overweight on October 12, 2026, and the shares rose about 4% early, according to published market data. Overweight means the analyst expects the stock to outperform comparable companies over the coming year, which is an opinion …
The biotech calendar for October 12 to 20, 2026 includes Edgewise Therapeutics data at the Heart Failure Society of America meeting on October 12, an Arrowhead Pharmaceuticals webinar on ARO-MAPT on October 14 at 11:30 a.m. PT, and a Regenxbio sura-vec event on October …
Merck (NYSE:MRK) presented one-year results for remigromig in diabetic macular edema, a swelling of the central retina caused by leaking vessels in people with diabetes. Vision improved by 9.1 and 8.7 letters in two groups compared with 11.8 letters for ranibizumab, the established injection …
Edgewise Therapeutics (NASDAQ:EWTX) presented data at the Heart Failure Society of America meeting on October 12, 2026, according to company event notices. The topic of the presentation was not captured in published information, so this article does not describe results or the program involved. …
Medtronic (NYSE:MDT) rose 3.9% on October 12, 2026, the largest advance among five medical technology names. The company makes devices for heart, spine, surgical and diabetes care, and sells them to hospitals worldwide, so its revenue depends on procedure volumes and hospital budgets. No …
STERIS (NYSE:STE) supplies infection prevention and surgical products to hospitals, and it agreed on October 12, 2026 to pay USD 2.1 billion for Xodus Medical. The company announcement describes a tax benefit of about USD 300 million, which lowers the net cost to about …
Please wait processing your request...